TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02808728
Drug: Pain Cocktail with Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pain cocktail: ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation.
Study: NCT02560155
Drug: Mupirocin 2% nasal ointement
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin nasal ointement 2x/d for 5 days preoperatively
Study: NCT02560155
Drug: Chlorhexidine sol 4%
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
Study: NCT02323646
Drug: Telapristone Acetate
Normalized name: Telapristone acetate
DrugBank: Telapristone acetate (DB05253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telapristone acetate, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
Study: NCT01370525
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
Study: NCT01154348
Drug: S-707106
Normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, taken once daily with morning meal
Study: NCT01154348
Drug: Metformin, S-707106 plus metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin twice daily maintenance, S-707106 tablet taken once daily with morning meal with metformin dosed twice daily
Study: NCT01154348
Drug: Metformin, placebo plus metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin twice daily maintenance, placebo tablet taken once daily with morning meal with metformin twice daily
Study: NCT01544998
Drug: Nesiritide
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 ug/kg
Study: NCT01544998
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg
Study: NCT03284034
Drug: ATX-101
Normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The right and left sides of the upper back fat will be randomly assigned to receive The right and left sides of the upper back fat will be randomly assigned to receive ATX-101 (deoxycholic acid) injections, 3 sessions, 30 days apart.
Study: NCT03056482
Drug: Ondansetron 8mg
Normalized name: ONDANSETRON 8MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 8 MG prepared in a 100 mL normal saline min-bag
Study: NCT03056482
Drug: Haloperidol 0.05mg/kg
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 0.05 mg/kg prepared in a 100 mL normal saline min-bag
Study: NCT03056482
Drug: Haloperidol 0.1mg/kg
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 0.1 mg/kg prepared in a 100 mL normal saline min-bag
Study: NCT02391636
Drug: Carbetocin
Normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: at delivery of anterior shoulder
Study: NCT02391636
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: at delivery of anterior shoulder
Study: NCT00710606
Drug: NuvaRing
Normalized name: NuvaRing
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
Study: NCT00710606
Drug: NuvaRing
Normalized name: NuvaRing
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
Study: NCT00303056
Drug: HOE140 Icatibant
DrugBank: Icatibant (DB06196)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00569673
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00569673
Drug: trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00514683
Drug: low dose BIBF1120 once daily
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low dose BIBF1120 once daily
Study: NCT00514683
Drug: low dose BIBF 1120 twice daily
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low dose BIBF 1120 twice daily
Study: NCT00664898
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Escalating intravenous repeating dose
Study: NCT00664898
Drug: SGN-40
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Escalating intravenous repeating dose
Study: NCT04546399
Drug: Calaspargase Pegol
Normalized name: Calaspargase pegol
DrugBank: Calaspargase pegol (DB14730)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04546399
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT04546399
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT04546399
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IM or IV
Study: NCT04546399
Drug: Pegcrisantaspase
Normalized name: Pegcrisantaspase
DrugBank: Pegcrisantaspase (DB16281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IM or IV
Study: NCT04546399
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV push or via infusion
Study: NCT02910700
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02910700
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02910700
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02910700
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02393807
Drug: PF 06260414 solid dose formulation
Normalized name: PF-06260414
DrugBank: PF-06260414 (DB15221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 30 mg PF-06260414 given under fed/fasted conditions
Study: NCT02393807
Drug: PF-06260414 nanosuspension
Normalized name: PF-06260414
DrugBank: PF-06260414 (DB15221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 30 mg PF-06260414 given under fasted conditions
Study: NCT01242748
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. In the main CS35 trial, a starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the degarelix treated participants continued to receive degarelix 480 mg s.c. treatment every three months.
Study: NCT01242748
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. In the main CS35 trial, an initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the goserelin treated participants continued to receive goserelin acetate 10.8 mg s.c. implants every three months.
Study: NCT02417103
Drug: GLP-1 (Liraglutide)
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: rGLP-1 (DB05433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 Analogon
Study: NCT03480191
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin will be given by intravenous infusion and administered over a 30 minutes infusion, daily, for 8 days and at the dosis of 10mg/kg/day.
Study: NCT04325425
Drug: Cisplatin injection
Normalized name: cisplatin Injection
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2, IV infusion over 3 hours or Carboplatin AUC 5, IV infusion over 30 minutes on day 1 \[the dose of carboplatin will be determined for each cycle using the Calvert's formula (carboplatin dose (mg) = target AUC 5 x estimated glomerular filtration rate (eGFR, mL/min) + 25)\];~• Etoposide 100 mg/m² IV infusion over 1 hour on day 1,2 and 3
Study: NCT02031367
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid arm
Study: NCT04237792
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan
Study: NCT04237792
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol IV administration will be given if needed to maintain sedation
Study: NCT03395184
Drug: PF-06651600
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg QD for 8 weeks, followed by 50 mg QD up to 56 weeks
Study: NCT03395184
Drug: Placebo PF-06700841
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks, followed by PF-06700841, 30 mg QD for 52 weeks
Study: NCT03395184
Drug: PF-06700841
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg QD for 12 weeks followed by 30 mg QD for up to 52 weeks
Study: NCT00790452
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 325 mg daily by mouth
Study: NCT03290456
Drug: Prednisone 5mg/day extended of 12 additional months
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 5mg/day orally during 12 Month + 1 mg/week tapering until 0mg.
Study: NCT01218048
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pre-Surgery: IV, 400 mg/m2 day 1 then 250 mg/m2 alone days 8 and 15; Post-surgery: IV, 250 mg/m2 weekly concurrent with RT
Study: NCT01290978
Drug: ChloraPrep
Normalized name: ChloraPrep
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The application sites (subjects' backs) will be prepped with ChloraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
Study: NCT02135107
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole 10 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
Study: NCT02135107
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole 20 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
Study: NCT02135107
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole 10 mg or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered once daily during the maintenance period (double-blind).
Study: NCT02135107
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole 10 or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered twice daily during the maintenance period (double-blind).
Study: NCT03088709
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV medication given for prevention of graft versus host disease.
Study: NCT03088709
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV medication given for prevention of graft versus host disease.
Study: NCT01218048
Drug: Cisplatin or carboplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m2 or carboplatin AUC 1.5-2/week weekly, Concurrent with radiotherapy
Study: NCT02578121
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4.0 mg will be given on days 1, 8 and 15 of a 28 day cycle
Study: NCT02578121
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4.0 mg will be given on days 1-21 of a 28 day cycle
Study: NCT02578121
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg will be given on days 1, 8, 15 and 22 of a 28 day cycle
Study: NCT01187498
Drug: Oxybutynin chloride, extended-release
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually titrated, extended-release oxybutynin chloride, initiated at 10 mg, fluid management handout, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
Study: NCT00650195
Drug: Metolazone Tablets 10 mg
Normalized name: metolazone Oral Tablet
DrugBank: Metolazone (DB00524)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg, single dose fasting
Study: NCT00251095
Drug: Taxol
Normalized name: Taxol
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00251095
Drug: TOCOSOL Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg/m2/week
Study: NCT03556852
Drug: Carbetocin
Normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby
Study: NCT03556852
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 rectal misoprostol tablets (800 μg) after the delivery of the baby.
Study: NCT01021748
Drug: MK-2206
Normalized name: MK-2206
DrugBank: MK-2206 (DB16828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT02048098
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 µg vaginal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg vaginal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
Study: NCT02048098
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 µg buccal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg buccal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
Study: NCT00301054
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00301054
Drug: Sulphadoxine-Pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02751294
Drug: Tafenoquine Control
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine
Study: NCT02751294
Drug: Tafenoquine SIL
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It will be compounded at site and will be administered as 0.3 mg/mL (100mL to be dosed, equivalent to 30 mg) aqueous Solution of SIL Tafenoquine.
Study: NCT03793725
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-angiogenic drugs
Study: NCT00519844
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02579876
Drug: Viaskin Milk 500 mcg
Normalized name: Milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological: Viaskin Milk 500 mcg Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
Study: NCT03152955
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine will be applied in patient-controlled analgesia.
Study: NCT00191282
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study
Study: NCT00191282
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine injected subcutaneous (SC) once daily in the evening until patient completes study.
Study: NCT03152955
Drug: ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.
Study: NCT01498822
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
Study: NCT01609816
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients receive dasatinib PO every day (QD) for 6 months.
Study: NCT00994708
Drug: esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02889900
Drug: cediranib and olaparib
Normalized name: Olaparib
DrugBank: Cediranib (DB04849)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily~Dose reduction for both products is allowed
Study: NCT00881491
Drug: Mineral Trioxide Aggregate
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard material providing an apical barrier
Study: NCT00352092
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00352092
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02561494
Drug: Nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02561494
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00242372
Drug: Tesaglitazar 0.5
DrugBank: Tesaglitazar (DB06536)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05125575
Drug: Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)
Normalized name: metformin 1000 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One tablet of the Test (T) product was administered orally with 240 mL of water.
Study: NCT00361439
Drug: Mometasone
Normalized name: Mometasone
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs in each nostril once daily of nasal spray
Study: NCT03999697
Drug: Autologous chimeric antigen receptor T cell transfusing agent targeting CD22
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day with 100% of the total expected dosage after receiving lymphodepleting chemotherapy
Study: NCT02809105
Drug: linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration once daily
Study: NCT03204955
Drug: Sodium chloride /sodium acetate (16.4%)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Acetate is a sterile, nonpyrogenic solution of Sodium Acetate intended as an alternative to sodium chloride to provide sodium ion in parenteral (IV) fluid therapy.~Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.
Study: NCT03204955
Drug: Sodium chloride (23.4%)
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.
Study: NCT01855997
Drug: Peg-IFN alfa-2a
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received Peg-IFN alfa-2a prior to enrollment for at least 24 weeks. Dosing was chosen according to standard of care or at the discretion of the treating physician.